Beacon Biosignals applies artificial intelligence to electroencephalography (EEG) data, aiming to advance the understanding and treatment of brain health. The company's work sits at the intersection of neurotechnology and precision medicine, offering tools for pharmaceutical development, clinical research, and sleep diagnostics.
Its flagship product, Waveband, is a platform designed to support both clinical trials and home sleep diagnostics. The system enables multi-night EEG data collection in patients' natural sleep environments and has been used in over 40 clinical trials. Complementing this is the Dreem 3S headband, an FDA 510(k)-cleared device for home-based EEG data collection.
The company's core capability lies in integrating and analysing large volumes of neurological data. To date, its platform has processed over two million hours of EEG data. This data feeds into clinical trial design and biomarker discovery, serving clients in the pharmaceutical and clinical research sectors focused on neurological and psychiatric diseases.
